Lipase-catalyzed Synthesis of Ergosterol Ester and Its Preventive Effect on Nonalcoholic Fatty Liver Disease
Article
Figures
Metrics
Preview PDF
Reference
Related
Cited by
Materials
Abstract:
The lipase-catalyzed synthesis of ergosterol linoleate was explored, along with its potential role in mitigating non-alcoholic fatty liver disease (NAFLD). Thirty male Kunming mice were divided into four groups: blank (n=6), high-fat (n=8), ergosterol (n=8), and ergosterol linoleate (n=8). The mice were fed for six weeks. Plasma levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were determined. LDL-C/HDL-C ratio was calculated, and lipid levels in the liver and feces were measured, along with the degree of liver fat degeneration. The results showed that ergosterol linoleate could be successfully synthesized using Candida sp. 99-125 lipase as a catalyst. Ergosterol ester reduced the total fatty acid content in the liver by 35.3% (P<0.05), effectively preventing high-fat diet-induced liver fat degeneration, and increased fecal total fatty acid levels by 74.8% (P<0.05). Meanwhile, ergosterol ester decreased plasma LDL-C levels and LDL-C/HDL-C ratio by 24.3% (P<0.05) and 36.5% (P<0.05), respectively, and increased plasma HDL-C levels by 52% (P<0.05). These results indicate that ergosterol ester can effectively prevent high-fat diet-induced NAFLD. This study provides a new dietary intervention strategy for the prevention of NAFLD.
